Capital Research Global Investors Cuts Stake in Thermo Fisher Scientific Inc. $TMO

Capital Research Global Investors lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,914,901 shares of the medical research company’s stock after selling 247,761 shares during the quarter. Capital Research Global Investors’ holdings in Thermo Fisher Scientific were worth $1,689,072,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of TMO. High Note Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares during the period. JPL Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth $28,000. Beacon Financial Strategies CORP acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $29,000. Olistico Wealth LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $29,000. Finally, Core Wealth Advisors LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $30,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Activity

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on TMO shares. Stifel Nicolaus lowered their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. DZ Bank started coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They set a “buy” rating and a $610.00 price target on the stock. Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Finally, KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $613.67.

Thermo Fisher Scientific Stock Down 1.9%

TMO stock opened at $472.98 on Friday. The company’s 50 day simple moving average is $479.94 and its 200-day simple moving average is $531.08. The firm has a market capitalization of $175.77 billion, a PE ratio of 26.00, a P/E/G ratio of 2.09 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.